For those who are familiar with the company, there are two really remarkable things about Array. One is our ability to discover products compounds that stand at test of time, so INDs have been filed on 18 Array invented compounds, 15 of those are still in development, and 10 of those are in Phase 2 which is pretty remarkable track record.
The other is the ability to attract and enter into very valuable partnerships with great companies such as AstraZeneca, Novartis, Celgene, Roche, Amgen and others. And perhaps there is importantly to garner very impressive financials, so just last year we entered into an agreement with Genentech on Chk-1 preclinical compound in a tough biotech market $30 million upfront, as many as $700 million in milestone and double-digit royalty.
In total in fact, if you look at our partnered portfolio, we have as many as $3.4 billion in potential milestones before royalty. And just in the last two to three year's we raised $170 million worth of non-dilutive financing from the partnerships.
So, I'll just talk for a couple of minutes about our internal pipeline and touch on our partnered pipeline and then open up for some questions. So, of the five products which we see potential entering Phase 3 and by the end of next year two of those (inaudible) products. So, as of our last quarter call we have been very clear that internally we are focused on developing and commercializing HemOnc product.Our first product is ARRY-614 for myelodysplastic syndromes and we are targeting and publishing about 100,000 Int-1 low risk myelodysplastic syndrome patients let's say about two-thirds of the total. We are looking within that group at HMA failures patients who have no choice, no other therapeutic option and have a very poor prognosis. So, thus far we have shown that a 40% response rate with multi-lineage response in that population, we are setting a new much more potent formulation, more bio available and expect that data to fully mature by the beginning and next year.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV